EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?

Beata Kaleta iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Beata Kaleta. Beteiligte Einrichtung: Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Autoimmune Diseases, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenAutoimmune DiseasesKidney DiseasesT-LymphocytesHumansAnimalsB-LymphocytesCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

autoimmune kidney diseasechimeric antigen receptorimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.

ORCID-Profile: Beata Kaleta

Zitieren

APA

Kaleta, B. (2025). CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010070

Vancouver

Kaleta B. CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010070

BibTeX
@article{Kaleta2025,
  author = {Kaleta, Beata},
  title = {CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010070}
}
Kostenlos starten →